Mostrar el registro sencillo del ítem
Mrna vaccines against sars-cov-2: advantages and caveats
dc.creator | Echaide Górriz, Míriam | es_ES |
dc.creator | Chocarro, Luisa | es_ES |
dc.creator | Bocanegra Gondán, Ana Isabel | es_ES |
dc.creator | Blanco, Ester | es_ES |
dc.creator | Kochan, Grazyna | es_ES |
dc.creator | Escors Murugarren, David | es_ES |
dc.date.accessioned | 2023-08-11T06:50:30Z | |
dc.date.available | 2023-08-11T06:50:30Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Echaide, M., Chocarro De Erauso, L., Bocanegra, A., Blanco, E., Kochan, G., & Escors, D. (2023). Mrna vaccines against sars-cov-2: Advantages and caveats. International Journal of Molecular Sciences, 24(6), 5944. https://doi.org/10.3390/ijms24065944 | en |
dc.identifier.issn | 1661-6596 | |
dc.identifier.uri | https://hdl.handle.net/2454/45919 | |
dc.description.abstract | The application of BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2 infection has constituted a determinant resource to control the COVID-19 pandemic. Since the beginning of 2021, millions of doses have been administered in several countries of North and South America and Europe. Many studies have confirmed the efficacy of these vaccines in a wide range of ages and in vulnerable groups of people against COVID-19. Nevertheless, the emergence and selection of new variants have led to a progressive decay in vaccine efficacy. Pfizer–BioNTech and Moderna developed updated bivalent vaccines—Comirnaty and Spikevax—to improve responses against the SARS-CoV-2 Omicron variants. Frequent booster doses with monovalent or bivalent mRNA vaccines, the emergence of some rare but serious adverse events and the activation of T-helper 17 responses suggest the need for improved mRNA vaccine formulations or the use of other types of vaccines. In this review, we discuss the advantages and limitations of mRNA vaccines targeting SARS-CoV-2 focusing on the most recent, related publications. | en |
dc.description.sponsorship | The OncoImmunology group is funded by the Spanish Association against Cancer (AECC, PROYE16001ESCO); Instituto de Salud Carlos III (ISCIII)-FEDER project grants (FIS PI17/02119, FIS PI20/00010, COV20/00000, and TRANSPOCART ICI19/00069); a Biomedicine Project grant from the Department of Health of the Government of Navarre (BMED 050-2019); Strategic projects from the Department of Industry, Government of Navarre (AGATA, Ref 0011-1411-2020-000013; LINTERNA, Ref. 0011-1411-2020-000033; DESCARTHES, 0011-1411-2019-000058); This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 848166. | en |
dc.format.mimetype | application/pdf | en |
dc.language.iso | eng | en |
dc.publisher | MDPI | en |
dc.relation.ispartof | International Journal of Molecular Sciences, 2023, 24, 5944 | en |
dc.rights | © 2023 by the authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. | en |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | BNT162b2 | en |
dc.subject | Comirnaty | en |
dc.subject | MRNA vaccines | en |
dc.subject | MRNA-1273 | en |
dc.subject | Myocarditis | en |
dc.subject | SARS-CoV-2 | en |
dc.subject | Spikevax | en |
dc.subject | Th17 response | en |
dc.subject | Variants | en |
dc.title | Mrna vaccines against sars-cov-2: advantages and caveats | en |
dc.type | Artículo / Artikulua | es |
dc.type | info:eu-repo/semantics/article | en |
dc.date.updated | 2023-08-11T06:19:44Z | |
dc.contributor.department | Ciencias de la Salud | es_ES |
dc.contributor.department | Osasun Zientziak | eu |
dc.rights.accessRights | Acceso abierto / Sarbide irekia | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | en |
dc.identifier.doi | 10.3390/ijms24065944 | |
dc.relation.projectID | info:eu-repo/grantAgreement/European Commission/Horizon 2020 Framework Programme/848166 | en |
dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI17%2F02119/ES/ | en |
dc.relation.projectID | nfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI20%2F00010/ES/ | en |
dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/ICI19%2F00069/ES/ | en |
dc.relation.projectID | info:eu-repo/grantAgreement/Gobierno de Navarra//050-2019 | en |
dc.relation.projectID | info:eu-repo/grantAgreement/Gobierno de Navarra//0011-1411-2020-000013 | en |
dc.relation.projectID | info:eu-repo/grantAgreement/Gobierno de Navarra//0011-1411-2020-000033 | en |
dc.relation.projectID | info:eu-repo/grantAgreement/Gobierno de Navarra//0011-1411-2019-000058 | en |
dc.relation.publisherversion | https://doi.org/10.3390/ijms24065944 | |
dc.type.version | Versión publicada / Argitaratu den bertsioa | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | en |